Program
Preliminary Program
Thursday November 10, 2022
Pediatric Pulmonary Hypertension, A short introductory update course:
-
Diagnostic work up in 2022, the essentials
-
Current treatment strategies in 2022, the essentials
Molecular mechanisms of PAH, towards new therapies?
-
Pulmonary vascular remodeling, lessons to be learned from systemic atherosclerosis
-
The role of Inflammasome in the pathobiology of PAH
-
New PAH therapies to emerges: from pediatric trials and pre-clinical work
The new hemodynamic definition of PH: consequences for pediatric PH
-
Changing definition, changing disease? Panel discussion
Advanced intensive care for pediatric PAH
-
Lessons from a Potts-program
-
Lessons from a pediatric ECLS program
-
Lessons from a pediatric Lung transplant program
-
The role of ex-vivo perfusion in increasing donor lung availability
Case presentations
Down syndrome and PH in children
-
Clinical lung diseases in trisomy 21
-
Genetic aspects of pulmonary (vascular) disease in trisomy 21
-
PAH in children with versus without trisomy 21
Friday, November 11 2022
How to monitor your pediatric PAH patient
-
risk stratification and risk scores in pediatric PAH
-
Clinical value of new imaging techniques in monitoring pediatric PAH
-
When to assess your PH-patient: At rest or during exercise
New technologies in medicine, applicable in the pediatric PAH arena:
-
Nanomotors and photoregulation, borders to cross (preliminary Prof Feringa, Nobel prize winner Chemistry 2016)
-
The E-nose for diagnosing PAH using
-
Wearables and implantables in monitoring PH
-
Artificial Intelligence, applications in pediatric PAH
Neonatal pulmonary vascular disease
-
Diagnosing pulmonary hypertension in preterms: when and how?
-
Developmental lung disease” how to move forward…?
-
PH and BPD
-
PH and CDH (Novel Approaches to Developmental Lung Diseases of the Pulmonary Vasculature)
-
Fetal growth restriction, pre-ecclampsia and neonatal pulmonary vascular disease, common vascular pathophysiology
-
Preventive treatment strategies for preterms at risk for developing BPD or late PH
Three Best Posters: Short oral communications
Deep phenotyping in pediatric PVD
-
Genetics, epi-genetics (Genotype-Phenotype relations in pediatric PAH)
-
Sex, sex hormones and ethnicity affecting RV and pulmonary vascular disease
-
Associated conditions and comorbidities in Pediatric PVD: cause, modifier or bystander
-
PVDOMICS-initiative and biomarkers: significance in pediatric PVD (provisional Allan Everett)
COVID-19 and PH in children
-
maternal COVID infection in the 3rd trimester of pregnancy increases the risk for PPHN
-
COVID-19 in pre-existing PAH
Social Program
Welcome dinner
On November 10 we will enjoy the conference dinner.
The dinner is included in the registration fee.
Good-bye dinner
On November 11 there will be a Good-bye dinner, you can indicate during your registration if you want to join (price €50,00)